AHMEDABAD: Sentynl Therapeutics Inc (Sentynl), a US-based biopharmaceutical firm wholly owned by Ahmedabad-headquartered Zydus Lifesciences, not too long ago accomplished the acquisition of global proprietary rights for Zokinvy. Zokinvy is the primary and solely US FDA-approved treatment focusing on the trigger and signs of Progeria in younger individuals above 12 months of age.
Progeria, which encompasses Hutchinson-Gilford Progeria Syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PDPL), are ultra-rare, deadly, genetic untimely getting old illnesses that speed up mortality in younger sufferers.
After receiving USFDA approval in 2020, Zokinvy additionally obtained approval within the European Union and Great Britain (2022) and in Japan (January 2024). This growth of Zydus’ portfolio consists of medicines for uncommon illnesses.
“This acquisition signifies an important milestone in expanding our portfolio of medicines for rare and orphan diseases, which can have devastating consequences if left untreated. We are dedicated to supporting patients in living healthier and more fulfilling lives,” acknowledged a consultant from Zydus.
“By adding Zokinvy to our portfolio of products, we aim to address the needs of rare disease patients, whose requirements are often unmet or disregarded,” commented Matt Heck, president & CEO of Sentynl.
Audrey Gordon, President and Executive Director of The Progeria Research Foundation (PRF), remarked, “Without Zokinvy therapy, children with Progeria succumb to the same heart disease that affects millions of normally aging adults, but at an average age of 14.5 years old. Zokinvy provides these beautiful children with longer, healthier lives.”
Progeria, which encompasses Hutchinson-Gilford Progeria Syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PDPL), are ultra-rare, deadly, genetic untimely getting old illnesses that speed up mortality in younger sufferers.
After receiving USFDA approval in 2020, Zokinvy additionally obtained approval within the European Union and Great Britain (2022) and in Japan (January 2024). This growth of Zydus’ portfolio consists of medicines for uncommon illnesses.
“This acquisition signifies an important milestone in expanding our portfolio of medicines for rare and orphan diseases, which can have devastating consequences if left untreated. We are dedicated to supporting patients in living healthier and more fulfilling lives,” acknowledged a consultant from Zydus.
“By adding Zokinvy to our portfolio of products, we aim to address the needs of rare disease patients, whose requirements are often unmet or disregarded,” commented Matt Heck, president & CEO of Sentynl.
Audrey Gordon, President and Executive Director of The Progeria Research Foundation (PRF), remarked, “Without Zokinvy therapy, children with Progeria succumb to the same heart disease that affects millions of normally aging adults, but at an average age of 14.5 years old. Zokinvy provides these beautiful children with longer, healthier lives.”
